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Abstract
The antinociceptive effect of the D2 antagonist prochlorperazine was examined in the mouse hot-plate and abdominal constriction
tests. Prochlorperazine (1–2 mg kg−1 s.c./i.p.) produced an increase of the pain threshold in the mouse hot-plate test. The antinociception
produced by prochlorperazine was prevented by the D2 selective agonist quinpirole, the unselective muscarinic antagonist atropine, the M1
selective antagonist pirenzepine, and by the choline uptake inhibitor hemicholinium-3 hydrobromide (HC-3). Moreover, prochlorperazine
antinociception was abolished by pretreatment with an aODN against the M1 receptor subtype, administered at the dose of 2 nmol per
single i.c.v. injection. By contrast the analgesic effect of prochlorperazine was not prevented by the opioid antagonist naloxone and the
GABAB antagonist CGP-35348. Prochlorperazine also elicited a dose-dependent increase in ACh release from rat cerebral cortex. In the
antinociceptive dose-range, prochlorperazine did not impair mouse performance evaluated by the rota-rod and hole-board tests. On the basis
of the above data, it can be postulated that prochlorperazine exerted an antinociceptive effect mediated by a central cholinergic mechanism.
© 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
Prochlorperazine is a dopamine D2 receptor antago-
nist [1] clinically widely used for preventing nausea and
vomiting of different origin, such as those induced by
cyclophosphamide- and cisplatin-based chemotherapy [2,3]
by radiotherapy [4] or by surgery [5–7]. Prochlorperazine is
also effective, after intravenous administration, in the rapid
control of vomiting in the emergency department [8]. Fur-
thermore, several antiemetic preparations contain prochlor-
perazine in association with granisetron, dexamethason,
lorazepam, scopolamine, or nabilone [9–12]. Another ther-
apeutic use of prochlorperazine is the relief of migraine
attacks. Migraine is a very common pain syndrome. It is
a multifaceted disorder, of which the head pain is only
one component. A migraine attack is often accompanied
Abbreviations: aODN, antisense oligodeoxynucleotide; dODN, dege-
nerate oligodeoxynucleotide; HC-3, hemicolinium-3 hydrobromide; i.c.v.,
intracerebroventricular; i.p., intraperitoneal; s.c., subcutaneous
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by nausea, vomiting, diarrhoea, photophobia, phonophobia,
etc. [13]. Prochlorperazine is used, alone or in combina-
tion, in different forms of headache. In particular, positive
therapeutic results were obtained in migraine attacks or
tension-type and vascular headache [14–16]. Prochlorper-
azine is able not only to abolish nausea and vomiting, but
also to relief pain occurring during a migraine attack better
than metoclopramide [17].
Prochlorperazine, therefore, is endowed with antiemetic
properties. Furthermore, it seems able to exert an antialgesic
activity at least in headache attacks. Taking into account
these observations, the aim of the present study was to first
investigate the analgesic properties of prochlorperazine in
laboratory animals by using different nociceptive stimuli,
such as thermal and chemical. Then, we also investigated the
neurotransmitter system and receptor subtypes involved in
the increase of pain threshold induced by prochlorperazine
in order to elucidate its mechanism of action.
In order to exclude that the effects produced by prochlor-
perazine treatment were due to the induction of side ef-
fects, some additional behavioural tests, able to assess motor
co-ordination (rota rod), spontaneous motility and inspec-
tion activity (hole board), were performed.
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2. Methods
2.1. Animals
Male Swiss albino mice (23–25 g) and Wistar rats
(150–200 g) from the Morini (San Polo d’Enza, Italy) breed-
ing farm were used. Fifteen mice or five rats were housed
per cage (26 cm× 41 cm). The cages were placed in the ex-
perimental room 24 h before the test for acclimatisation. The
animals were fed a standard laboratory diet and tap water
ad libitum and kept at 23± 1 ◦C with a 12-h light:12-h dark
cycle, light on at 07.00 a.m. All experiments were carried
out in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) for experi-
mental animal care. All efforts were made to minimise the
number of animals used and their suffering.
2.2. Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was per-
formed under ether anaesthesia, according to the method
described by Haley and McCormick [18]. Briefly, during
anaesthesia, mice were grasped firmly by the loose skin
behind the head. A 0.4 mm external diameter, hypodermic
needle attached to a 10l syringe was inserted perpendic-
ularly through the skull and no more than 2 mm into the
brain of the mouse, where 5l was then administered. The
injection site was 1 mm to the right or left from the mid-
point on a line drawn through to the anterior base of the
ears. Injections were performed into the right or left ventri-
cle randomly. To ascertain that the drugs were administered
exactly into the cerebral ventricle, some mice (20%) were
injected with 5l of diluted 1:10 India ink and their brains
examined macroscopically after sectioning. The accuracy
of the injection technique was evaluated and the percentage
of correct injections was 95.
2.3. Hot-plate test
The method adopted was described by O’Callaghan and
Holtzman [19]. Mice were placed inside a stainless steel
container, thermostatically set at 52.5±0.1 ◦C in a precision
water-bath from KW Mechanical Workshop, Siena, Italy.
Reaction times (s) of each animal were measured with a
stop-watch before and at regular intervals up to a maximum
of 60 min after treatment. The endpoint used was the licking
of the fore or hind paws. Before pretreating animals, a pretest
was performed: those mice scoring below 12 and over 18 s
in the pretest were rejected (30%). An arbitrary cut-off time
of 45 s was adopted. At least seven animals per group were
used.
2.4. Abdominal constriction test
Mice were injected i.p. with a 0.6% solution of acetic acid
(10 ml kg−1), according to Koster et al. [20]. The number
of stretching movements was counted for 10 min, starting
5 min after acetic acid injection. At least 10 animals per
group were used.
2.5. Hole-board test
The hole board test consisted of a 40 cm square plane
with 16 flush mounted cylindrical holes (3 cm diameter) dis-
tributed 4×4 in an equidistant, grid-like manner. Mice were
placed on the centre of the board one by one and allowed
to move about freely for a period of 10 min each. Two elec-
tric eyes, crossing the plane from mid-point to mid-point of
opposite sides, thus dividing the plane into four equal quad-
rants, automatically signalled the movement of the animal
(counts in 5 min) on the surface of the plane (locomotor ac-
tivity). Miniature photoelectric cells, in each of the 16 holes,
recorded (counts in 5 min) the exploration of the holes (ex-
ploratory activity) by the mice.
2.6. Rota-rod test
The apparatus consisted of a base platform and a rotating
rod with a diameter of 3 cm and a non-slippery surface. The
rod was placed at a height of 15 cm from the base. The
rod, 30 cm in length, was divided into five equal sections by
six disks. Thus, up to five mice were tested simultaneously
on the apparatus, with a rod-rotating speed of 16 rpm. The
integrity of motor co-ordination was assessed on the basis
of the number of falls from the rod in 30 s according to
Vaught et al. [21]. Before pretreating animals, a pretest was
performed: mice scoring less than 3 and more than six falls
in the pretest were rejected (20%). The performance time
was measured before (pretest) and 15, 30 and 45 min after
s.c. treatment.
2.7. Antisense oligonucleotides
Low cell permeability and the high degradation of natu-
ral phosphodiester oligomers are considerable drawbacks in
the application of aODNs both in vitro and in vivo. To over-
come these drawbacks, phosphorothioate-capped phospho-
rodiester oligonucleotides were used. The above-mentioned
compounds are a class of ODN derivatives shown to
maintain more stable and effective concentrations in the
brain when compared with their unmodified counterpart
[22]. Phosphodiester oligonucleotides (ODNs) protected
by terminal phosphorothioate double substitution (capped
ODNs) against possible exonuclease-mediated degradation
were purchased from Genosys (Cambridge, England, UK)
and purified by high-performance liquid chromatography
(HPLC). The 18-mer antisense ODN (aODN) 5′-CXAXC
TGA GGT GTT CAT TXGXC-3′ (X: phosphorothioate
residues) complementary to the residues 112–129 of the
published mouse M1 cDNA sequence [23] and the 18-mer
fully degenerated ODN (dODN) 5′ NNN NNN NNN
NNN NNN-3′ (where N is G, or C, or A, or T and
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phosphorothioate residues are underlined) were vehicu-
lated intracellularly by an artificial cationic lipid (DOTAP,
Boehringer-Mannheim, Germany) to enhance both up-
take and stability. aODN or dODN (100–400M) were
preincubated at 37 ◦C for 30 min with 13M DOTAP,
sterilised through a 0.2m filter and supplied to mice by
i.c.v. injection of a 5l solution as described in the next
section.
The accession number of the cDNA sequence for the
mouse muscarinic receptor subtype reported in this paper
(M1) is J04192.
2.8. Determination of ACh release by cerebral
microdialysis
Microdialysis was performed in rat parietal cortex accord-
ing to Giovannini et al. [24]. The co-ordinates used for the
implantation of the microdialysis tubing (AN 69 membrane,
molecular weight cut off >15 kDa, Dasco, Italy) were AP
0.5 mm and H 2.3 mm from the bregma [25]. One day af-
ter surgery the microdialysis tubing was perfused at a con-
stant flow rate (2l min−1) with Ringer solution (NaCl 147,
KCl 4.0, CaCl21.2 mM) containing 7M physostigmine sul-
phate. After a 1 h settling period the perfusate was collected
at 15 min intervals in test tubes containing 5l of 0.5 mM
HCl to prevent ACh hydrolysis. The samples were then as-
sayed for ACh content either immediately or after freezing.
ACh was detected and quantified by HPLC with an electro-
chemical detector, as described by Damsma et al. [26] and
Giovannini et al. [27].
2.9. Drugs
The following drugs were used: morphine hydrochlo-
ride (S.A.L.A.R.); hemicholinium-3 hydrobromide (HC-3),
pirenzepine dihydrochloride, naloxone hydrochloride,
(−)-quinpirole, hydrochloride (RBI); atropine sulphate,
prochlorperazine dimaleate, amitriptyline hydrochloride,
(±)-baclofen, DOTAP (Sigma); CGP-35348 (Ciba Geigy);
d-amphetamine hydrochloride (De Angeli). All drugs were
dissolved in isotonic (NaCl 0.9%) saline solution imme-
diately before use. Drug concentrations were prepared in
such a way that the necessary dose could be administered
in a volume of 10 ml kg−1 by s.c. or i.p. injection or 5l
per mouse by i.c.v. injection.
2.10. Statistical analysis
All experimental results are given as the mean ± S.E.M.
ANOVA, followed by Fisher’s Protected Least Significant
Difference (PLSD) procedure for post hoc comparison,
was used to verify significance between two means. Data
were analysed with the StatView software for the Macin-
tosh (1992). P values of less than 0.05 were considered
significant.
Fig. 1. Dose–response curve of prochlorperazine (i.p.) in mouse hot-plate
test. Each point represents the mean of at least seven mice. ∗P < 0.01;
ˆP < 0.05 in comparison with saline-treated mice.
3. Results
3.1. Antinociceptive activity of prochlorperazine
Prochlorperazine, as shown in Fig. 1, increased the pain
threshold in the mouse hot-plate test after i.p. adminis-
tration (1–2 mg kg−1) whereas the dose of 0.3 mg kg−1
i.p. was devoid of any effect. Prochlorperazine was able
to induce antinociception also in the mouse abdominal
constriction test. At the dose of 1 mg kg−1 s.c., prochlor-
perazine induced antinociception of intensity comparable
to that exerted by well known analgesic drugs such as mor-
phine (1 mg kg−1 s.c.), and amitriptyline (5 mg kg−1 s.c.)
(Fig. 2). A dose 10-time lower of prochlorperazine as well
as the above-mentioned reference compounds, was devoid
of any effect (Fig. 2).
3.2. Antagonism of prochlorperazine antinociception
In the mouse hot-plate test, the antinociceptive effect
of prochlorperazine (2 mg kg−1 i.p.) was antagonized by
the unselective muscarinic antagonist atropine (5 mg kg−1
i.p.), the selective M1 muscarinic antagonist pirenzepine
(0.1g per mouse i.c.v.), the choline uptake inhibitor HC-3
(1g per mouse i.c.v.) and the D2 agonist quinpirole (0.5g
per mouse i.c.v.) (Table 1). Otherwise, the opioid antag-
onist naloxone (1 mg kg−1 i.p.) and the GABAB antago-
nist CGP-35348 (100 mg kg−1 i.p.) were unable to prevent
prochlorperazine antinociception (Table 1). The minimal
dose of quinpirole able to prevent prochlorperazine antinoci-
ception was 0.5g per mouse i.c.v., a concentration unable
to modify morphine (7 mg kg−1 s.c.) and the GABAB ag-
onist baclofen (4 mg kg−1 i.p.)-induced antinociception. By
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Fig. 2. Antinociceptive effect of prochlorperazine in comparison with morphine and amitriptyline in mouse abdominal constriction test. Nociceptive
response was recorded 30 min after drug administration (s.c.). ∗P < 0.01 in comparison with saline-treated mice. Each column represents the mean of at
least 10 mice.
contrast, the dose of 0.1g per mouse i.c.v. of quinpirole
was ineffective (Fig. 3).
All antagonists were injected 15 min before the test, with
the exception of HC-3 injected 5 h before the test.
Pretreatment with a single (2 nmol per mouse i.c.v.) in-
jection of antisense ODN (aODN) to M1 gene on days 1, 4
and 7, prevented prochlorperazine-induced increase of pain
threshold in the mouse hot-plate 24 h after the last i.c.v. in-
jection (Fig. 4). This antagonistic effect was not detected
in the dODN-treated group, used as control ODN (Fig. 4).
Forty-eight hours after the end of the treatment, a partial
reversion of prochlorperazine antinociception was detected,
whereas after 96 h, prochlorperazine induced an antinoci-
Table 1
Effect of atropine, pirenzepine, HC-3, quinpirole, naloxone and CGP-35348 on antinociception induced by prochlorperazine (2 mg kg−1 i.p.) in the mouse
hot-plate test
Pretreatment Licking latency (s)
Treatment Before After treatment
30 min 45 min 60 min
Saline-prochlorper. Saline 13.6 ± 0.7 14.4 ± 1.0 13.9 ± 0.9 14.3 ± 0.8
14.6 ± 0.9 25.1 ± 1.8∗ 27.2 ± 1.6∗ 23.8 ± 1.6∗
Atropine (5 mg kg−1 i.p.) Saline-prochlorper. 14.0 ± 0.7 13.3 ± 1.3 13.1 ± 1.1 14.2 ± 1.3
13.9 ± 1.0 17.2 ± 1.7∗∗∗ 17.8 ± 2.0∗∗∗ 15.1 ± 1.7∗∗∗
Pirenzepine (0.1g i.c.v.) Saline-prochlorper. 14.1 ± 1.2 14.2 ± 1.5 13.8 ± 1.4 14.5 ± 1.6
14.2 ± 1.3 16.2 ± 1.8∗∗∗ 15.4 ± 1.9∗∗∗ 16.0 ± 2.1∗∗∗
HC-3 (1g i.c.v.) Saline-prochlorper. 14.4 ± 0.9 13.8 ± 1.5 15.5 ± 1.3 15.4 ± 1.2
14.4 ± 1.1 18.0 ± 2.1∗∗∗ 16.5 ± 1.7∗∗∗ 15.3 ± 1.5∗∗∗
Quinpirole (0.5g i.c.v.) Saline-prochlorper. 14.4 ± 0.9 14.8 ± 1.5 15.5 ± 1.3 15.4 ± 1.2
15.0 ± 1.1 17.3 ± 13∗∗∗ 16.9 ± 1.6∗∗∗ 14.2 ± 1.5∗∗∗
Naloxone (1 mg kg−1 i.p.) Saline-prochlorper. 13.5 ± 0.8 14.0 ± 1.5 13.9 ± 1.6 14.3 ± 1.7
13.5 ± 0.6 27.2 ± 2.4∗ 25.6 ± 2.0∗ 21.7 ± 2.4∗
CGP-35348 (100 mg kg−1 i.p.) Saline-prochlorper. 13.5 ± 0.7 11.4 ± 1.3∗∗ 12.5 ± 2.0 12.7 ± 1.5
13.5 ± 1.2 23.2 ± 1.7∗ 25.7 ± 2.5∗ 21.9 ± 1.7∗∗
∗ P < 0.01 in comparison with saline.
∗∗ P < 0.05 in comparison with saline.
∗∗∗ P < 0.01 vs. saline-prochlorperazine treated mice. The number of mice ranged from 8 to 26.
ceptive effect of the same intensity in aODN-, dODN- and
vehicle-treated mice indicating the loss of antagonistic ac-
tivity by the anti-M1 aODN (Fig. 4). The aODN pretreat-
ment (2.0 nmol per i.c.v. injection) did not reduce the pain
threshold in mice showing a lack of any hyperalgesic ef-
fect (Fig. 4). The pretreatment with the dODN did not mod-
ify prochlorperazine-induced antinociception in comparison
with mice injected with vehicle as shown in Fig. 4.
3.3. Effect of prochlorperazine on cerebral ACh levels
As shown in Fig. 5, prochlorperazine (2 mg kg−1 i.p.) sig-
nificantly increased the ACh release from cerebral cortex
C. Ghelardini et al. / Pharmacological Research 50 (2004) 351–358 355
Fig. 3. Effect of quinpirole on prochlorperazine-induced antinociception in mouse hot-plate test. Quinpirole was administered 5 min before the other drugs.
Nociceptive response was recorded 15 min after prochlorperazine (2 mg kg−1 i.p.) and 30 min after morphine (7 mg kg−1 i.p.) and baclofen (4 mg kg−1
s.c.) injection. Number of mice is reported inside the columns. ∗P < 0.01 vs. saline-treated mice. ◦P < 0.01 vs. prochlorperazine-treated mice.
of freely moving rats. The prochlorperazine curve repre-
sents the time-course of the increase expressed as percentage
change from the means of the three collection periods before
prochlorperazine administration, taken as control. Prochlor-
perazine ACh release peaked 30 min after administration and
returned to basal values within 120 min.
Fig. 4. Effect of antisense ODN (aODN) to M1 gene on prochlorperazine
(2 mg kg−1 i.p.)-induced antinociception 24, 48 and 96 h after the end of
the aODN treatment. Mice were i.c.v. injected with vehicle, aODN or
degenerated ODN (dODN) at the dose of 2.0 nmol per single i.c.v. injection
on days 1, 4 and 7. Modification of pain threshold was evaluated by using
the mouse hot-plate test. The licking latency was detected 30 min after
prochlorperazine administration. Vertical lines give SEM. Each column
represents the mean of 10–14 mice. ˆP < 0.05; ∗P < 0.01 in comparison
with vehicle-prochlorperazine-treated mice.
3.4. Effect of prochlorperazine on mouse behaviour
The spontaneous motility and exploratory behaviour of
mice was not modified by treatment with prochlorperazine
(2–3 mg kg−1 i.p.) as revealed by the hole-board test (Fig.
6). In the same experimental conditions d-amphetamine
(2 mg kg−1 s.c.), used as the reference drug, increased both
parameters evaluated.
The motor co-ordination of mice treated with prochlorper-
azine was evaluated by using the rota-rod test (Fig. 7). The
rota-rod performance of mice treated with prochlorperazine
Fig. 5. Effect of prochlorperazine on ACh release from rat cerebral cortex.
∗P < 0.01 in comparison with saline treated rats. Each point represents
the mean of three rats.
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Fig. 6. Lack of effect of prochlorperazine (PCP) in mouse hole-board
test in comparison with amphetamine. Test was performed 30 min after
PCP and amphetamine administration. ∗P < 0.01 in comparison with
saline-treated mice.
at the dose of 1–2 mg kg−1 i.p. was not impaired in compar-
ison with controls as indicated by a progressive reduction
of the number of falls. The number of falls by control an-
imals progressively decreased at every measurement since
the mice learnt how to balance on the rotating rod. By con-
trast, no reduction of the number of falls was observed after
administration of prochlorperazine at the dose of 3 mg kg−1
i.p. indicating the induction of motor incoordination
(Fig. 7).
4. Discussion
Prochlorperazine was showed to be able to induce
antinociception in mice. Antinociception was elicited re-
gardless of which noxious stimulus was used: thermal
(hot-plate test) and chemical (abdominal constriction test).
Prochlorperazine antinociception was obtained without pro-
ducing changes of animals’ gross behaviour. Moreover,
prochlorperazine-treated mice showed a complete integrity
of motor co-ordination on the rota-rod test, normal sponta-
Fig. 7. Dose–response curve of prochlorperazine in mouse rota-rod test.
∗P < 0.01 in comparison with saline controls. Each point represents the
mean of 10 mice.
neous motility, as well as exploratory behaviour as revealed
by the hole-board test.
The antinociceptive effect of prochlorperazine appears to
be due to the antagonism of D2 receptors since the increase
of the pain threshold induced by the investigated compound
was prevented by pretreatment with the D2 agonist quin-
pirole. Present data extend and support previous results in
which the capability of D2 antagonists to induce analge-
sia was suggested. Sulpiride was able to exert a potentiat-
ing effect of morphine analgesia in diabetic mice [28] and
the D2 blocker risperidone induced a potent increase of the
pain threshold in the mouse tail flick test [29]. Furthermore,
present results indicate that prochlorperazine antinocicep-
tion is dependent on central cholinergic activation. It should
be noted that several D2 antagonists, such as sulpiride, pipo-
tiazine and domperidone, increase K+ evoked ACh release
[30], whereas the D2 agonist quinpirole inhibit ACh ef-
flux [31,32] from rat striatal preparations. The increase of
the pain threshold induced by the investigated compound
was prevented by the non-selective muscarinic antagonist
atropine, the selective M1-antagonist pirenzepine, the ACh
depletor HC-3 and an aODN to the M1 receptor subtype.
The aODN treatment induces a transient prevention of mus-
carinic antinociception since the inhibition of prochlorper-
azine effect disappeared 96 h after the last i.c.v. injection
of the aODN. This return to normal sensitivity to analgesic
treatments implies both the total reversal of aODN-induced
specific inhibition of M1 gene expression and a lack of dam-
age or toxicity associated with aODN treatment.
Cholinergic antinociception in mice is mediated by M1
receptor stimulation. By using selective and unselective
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muscarinic agonists and antagonists, the involvement of M1
receptors in muscarinic analgesia was evidenced [33,34].
Furthermore, cholinergic antinociception induced both
directly, through muscarinic agonists, and indirectly, by
enhancing ACh extracellular levels through cholinesterase
inhibitors, is prevented by i.c.v. administration of an anti-
sense to the M1 gene coding for the mouse M1 receptor [35].
Taking into account that HC-3 and pirenzepine were able
to antagonise prochlorperazine antinociception after i.c.v.
injection, this indicates that the analgesic site of action of
the investigated compound is localised in the CNS.
A presynaptic mechanism facilitating cholinergic trans-
mission is involved in prochlorperazine antinociception as
revealed by the antagonism by HC-3 postsynaptic mecha-
nism of action can be ruled out since, as reported by Bartolini
et al. [33,36], HC-3 was not able to antagonise antinoci-
ception induced by agonists of postsynaptic muscarinic re-
ceptors such as oxotremorine, McN-A-343 and AF-102B.
The hypothesis of a presynaptic cholinergic mechanism for
prochlorperazine is further supported by microdialysis stud-
ies, in which an increase in ACh release from rat cerebral
cortex was induced by prochlorperazine administration. This
effect occurred at the same doses (2 mg kg−1 i.p.) in which
the investigated D2 antagonist exerted its antinociceptive ac-
tivity. The observed facilitation of the cholinergic transmis-
sion induced by prochlorperazine appears to be a conse-
quence of a blockade of D2 receptors.
Other neurotransmission systems able to modulate pain
threshold, such as opioid and GABAergic, are not involved
in prochlorperazine antinociception since the opioid antago-
nist naloxone and the GABAB antagonist CGP-35348 were
unable to prevent the effect of prochlorperazine. The doses
and administration schedules of the above-mentioned drugs
were ideal for preventing antinociception induced respec-
tively by morphine and the GABAB agonist baclofen.
In summary, our results have shown that prochlorper-
azine is able to produce antinociception without inducing
behavioural side effects, by potentiating endogenous cholin-
ergic activity through antagonism of D2 receptors.
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